PHP146 Pharmacoeconomic Education for Pharmacy Students in the Russian Federation  by Makhinova, T. et al.
Kockaya G1, Daylan Kockaya P2, Ergin Oguzhan G1
1Health Economics and Policy Association, Ankara, Turkey, 2Sile Government Hospital, Istanbul,
Turkey
OBJECTIVES: Health policy chances may effect the conducted studies in all fields.
Pharmacoeconomics dossiers for the reimbursement applications for new medi-
cines were not mandatory before year 2008. New molecules need to show cost-
effectiveness and possible budget effect with their applications for reimbursement
to Social Security Institution from 2008. This policy changing may effect pharmaco-
economics and health outcome studies in Turkey. The aim of the study is to eval-
uate the improvement of pharmacoeconomics and health outcome studies which
are specific for Turkey in years. METHODS: Database of ISPOR Outcome Research
Digest were searched online from the begining of database (1998) to 2011 with the
key words “Turkey” and “Turkish”. The inclusion criteria were taken as study must
be specific for Turkey. Included abstract evaluated for increasing abstract numbers
in years, distribution in study topics and diseases areas. RESULTS: A total of 108
abstracts were searched from the database; 80 of them were matched with inclu-
sion criteria. First abstracts were published in 2000. There were only one or two
abstracts per year until 2008. After year 2008, published abstracts numbers were
increased year by year and reached up to 18 per year in 2011. 55% of all abstracts
were Cost Studies(CS). It was followed by Health Care Use & Policy Studies(HP)
(13.7%) and Conceptual Papers (CP) (8,7%). 15% of all abstracts were Multipl Disease
studies. It was followed by Mental Health (15%) and Allergy(12.5%). CONCLUSIONS:
It was shown that the policy changing in 2008 as to require pharmacoeconomics
dossiers in the reimbursement application effected Turkey specific pharmacoeco-
nomic and health outcome studies positively. In other words, pharmaceutical ýn-
dustry and the government started to invest in pharmacoeconomics and health
outcome studies after 2008.
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OBJECTIVES: To analyze real occurrences of drug shortages throughout 2010 and
2012 and the underlying reasons. METHODS: We conducted a systematic search in
the scientific literature, media and public domain on occurrences of drug shortages
and the perceived underlying reasons. The type of drug shortages were categorized
and considered in context to their impact on access to medicines and health care
system efficiency. RESULTS: While there were 20 publications of any type around
this subject in Pubmed in 1995, the number increased with 34 in the year 2000, 70 in
2005, 99 in 2010, and 128 in 2011. The publications have discussed the health con-
sequences, workarounds, and the health consequences of the workarounds. In
February 2012, 110 drugs were listed on the FDA Web site, including at least 14
commonly used cancer chemotherapy drugs. Likewise, drug shortages are re-
ported in many countries around the world including European countries such as
Spain, France, UK, Russia, Portugal, Greece, or Rumania. Over the years, the reasons
for drug shortages have changed from being predominantly caused by shortages in
the active ingredients or insufficient distribution systems to currently often being
the consequences of strong cost-containment measures or economic crisis.
CONCLUSIONS: Drug shortages are increasingly observed over the last decade.
Drug shortages can have multiple reasons and are currently often induced by eco-
nomic or cost-containment reasons, and to misaligned incentives in the supply
chain.
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OBJECTIVES: The main hypothesis in this study is that stakeholders have different
preferences concerning IT innovations in hospitals, and these preferences are
caused by perceived cost/benefit ratios. This will translate in disagreement be-
tween stakeholders on which innovations to implement first, possibly explaining
the slow diffusion of innovations in health care. METHODS: Analytic Hierarchy
Process (AHP) was used to quantify stakeholders positions in their priority of nine
IT innovations. These innovations were selected after a systematic literature re-
view and expert interviews. In the AHP, decision criteria related to costs and ben-
efits of the innovations were defined: improvement in efficiency, health gains,
satisfaction with care process, and required investments. Stakeholders judged the
importance of the decision criteria and prioritized the selected IT innovations ac-
cording to their expectations of how well the innovations would perform on these
decision criteria. RESULTS: Sixty-two respondents, including patients, nurses,
physicians, managers, health care insurers and policy makers showed significant
differences in their expectations about their respective costs and benefits of the
innovations, resulting in diverging preferences for the health care innovations. For
instance, self tests are one of the most preferred innovations by health care insur-
ers and managers, due to its expected positive impacts on efficiency and health
gains. However, physicians, nurses and patients strongly doubt the health gains of
self tests, and accordingly rank self tests as the least preferred innovation.
CONCLUSIONS: We found clear differences in expectations of different stake-
holder groups on IT innovations. The differences can be understood from the per-
spective of costs and benefits per stakeholder for each innovation. This study gives
a first quantitative insight in stakeholder differences and presents a novel way to
study stakeholder differences. The results may be used by decision makers to
include alignment of stakeholder positions in implementation processes.
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OBJECTIVES: Clinical studies are the main drivers of innovation in drug research.
Pharmaceutical companies invest 15-20% of their revenue to clinical research for
developing new treatments. Due the high investment opportunities, countries take
actions to obtain the maximum share from global clinical studies market. Turkey
has a good potential due the geological location. The aim of the study is to show
possible economic effect of clinical studies to Turkey. METHODS: Application doc-
uments/files for the Ethic Committee of Istanbul Medical Facultyy were examined
from 2006 to 2010. Studies sponsored by pharmaceutical companies were included.
Pharmaceutical companies estimated budgets were accounted. Distribution of dif-
ferent disease areas of the studies and budgets were evaluated. RESULTS: Total
number of applications for clinical studies have risen from 177 to 252 from 2006 to
2010. All industry sponsored clinical trials were reported as 184 for the given time-
line. Approved sponsored pharmaceutical trials estimated total budget was € 859
million and Istanbul Medical Faculty could take € 59 million of all estimated budget
in given timeline. Average cost for per clinical trial and per patient were calculated
as € 467k and € 5k for Turkey. The highest estimated budget was hold by cardiolog-
ical trials with € 61 million, followed by oncology and norology with € 59 million for
the given timeline. CONCLUSIONS: It was shown that clinical trials may have a
great impact to Turkey‘s economy. If Turkey may increase new launched trials, this
is an opportunity for Turkey to take extra investment. Because these number are
below the potential of pharmaceutical trials investment amounts when compared
total pharmaceutical market. In addition, it is needed to account possible effects to
reimbursement agencies. Due the potential impact of clinical studies for Turkey,
decision and policy makers need to take action to improve clinical studies in Tur-
key.
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OBJECTIVES: To use a database of previous National Institute for Health and Clin-
ical Excellence (NICE) health technology assessment (HTA) decisions (HTA
inSite)1to understand the impact of four clinical evidence scenarios on the out-
come of NICE technology appraisals (TAs). METHODS: We identified published
NICE TAs containing evidence applicable to the following scenarios: 1) Efficacy data
with a non-significant but positive trend; 2) Surrogate endpoints used in place of
real endpoints; 3) Composite endpoints where statistical significance was driven by
some, but not all, of the individual components; and 4) Efficacy data from observa-
tional studies. For each scenario, multiple submissions and re-submissions were
identified using HTA inSite. The analysis focused on the evidence submitted, the
final decision and critique by NICE, and any changes in approach by the manufac-
turer at re-submission. RESULTS: Clear patterns emerged for each scenario. For
example NICE accepted data from surrogate endpoints (scenario 2) in all of the 4
submissions analysed. This was due to support by clinical experts and a clear
rationale for the surrogates as established markers of efficacy. Observational data
(scenario 4) were accepted in the absence of randomised controlled trials (RCTs), or
in addition to RCTs where long-term or country-specific evidence was required.
However, it was important to acknowledge and report any potential bias associated
with the design of observational studies. CONCLUSIONS: An evaluated database
can be used to understand the impact of any clinical evidence scenario on NICE
decisions. The results can be used to inform submission strategy and assess deci-
sion outcome risk.
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OBJECTIVES: One priority for improving Russian health care is the optimization of
health care resource use. Pharmacoeconomic (PE) methods allow economic evalu-
ation of pharmaceutical products and services. The objective of this study was to
investigate the extent of PE education in 2012 across pharmacy schools/depart-
ments in Russia. METHODS: A survey was e-mailed to 47 pharmacy schools listed
on the federal educational portal www.edu.ru. Follow-up phone calls were made to
non-respondents. Questions were used to determine: whether PE topics were
taught and under what discipline, whether it was a required (base) or elective
(variable) course, the number of academic hours dedicated to PE, the number of
students in the course, topics covered, resources used, an opinion of the instructor
on the sufficiency of the number of hours devoted to PE, and suggestions on PE
education improvement in pharmacy schools. RESULTS: Forty-three schools re-
plied to the survey (91.5% response rate). PE education was offered at 35 (81%)
schools of pharmacy: in 25 (58%) schools PE topics were covered under required
(base) course with median number of hours 3 (range 0.5-10, mean4) and in 10
(23%) schools PE topics were covered under elective (variable) course with median
number of hours 31 (range 16-54, mean32). Eight (19%) pharmacy schools did not
teach PE. The median numbers of students taking PE were 36 (range 12-220,
mean42) and 53 (range 24-350, mean86) for required (base) and elective (vari-
able) courses respectively. The majority of the instructors 22(63%) noted insuffi-
ciency of hours dedicated to PE. CONCLUSIONS: The majority of Pharmacy schools
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provide PE education, however the number of hours is sufficiently greater for
schools with an elective (variable) course in PE. In addition, results pertaining to the
opinions of key educators on the insufficiency of number of hours devoted to
PE-related topics and on enhancing PE education should be noted.
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OBJECTIVES: Early Access Programmes (EAPs) provide the possibility of making
medicines that address an unmet medical need available to patients before regu-
latory approval of the European Medicine Agency. Market Access includes market
development activities and patient access strategy, EAPs can positively impact
both areas. The aim of this review is to consider, compile and describe the main
EAPs available in Europe. METHODS: We conducted a review and performed a
mapping of EAPs systems that exists in Europe. We searched existing literature in
Embase, National Health Systems Website, ISPOR conference websites and Inter-
net. In the countries where information were more scattered we directly contacted
regulatory agencies and clinicians familiar with the local EAP regulations and
practices. RESULTS: We described the practical implications surrounding the reg-
ulatory framework for EAPs, the key stakeholders involved in EAP decision-making
and administration, the timelines for EAPs approval, and the key factors for suc-
cess. Many countries do not have an EAP in place and compassionate use is the only
route to market for unregistered or investigational products. This is the case for
Germany, Belgium, Poland, Austria and Switzerland. The markets where EAP are
more developed and sales are possible are: France, Spain, UK, Italy, Sweden, Den-
mark, Portugal, and Norway. CONCLUSIONS: This project made specific recom-
mendations on the most favourable countries, based on the ease of setting up such
a programme and the potential revenue that could result. At the time, there were
several countries where the legal framework was changing (e.g. Austria) and some
markets where information was simply not available.
HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment
Programs
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OBJECTIVES: Since January 2011 the new German AMNOG health care reform in-
cludes a mandatory EBA for innovative medicines. At time of launch pharmaceu-
tical companies have to submit a benefit dossier which is subsequently evaluated
by the Institute for Quality and Efficiency in Health Care (IQWiG). Our aim was to
explore differences in companies’ benefit claims and the respective IQWiG
assessments. METHODS: The review includes EBAs that were started in 2011. The
Joint Federal Committee’s (GBA) webpage was used to obtain the respective com-
panies’ benefit claims and IQWiG overall (i.e. aggregated, not on endpoint level)
benefit assessments. The GBA’s official scale is discriminating six levels of addi-
tional benefit versus comparative treatment: 1: major; 2: significant; 3: marginal; 4:
not quantifiable; 5: no benefit; 6: less benefit. IQWiG’s official evidence categories
include: 1: proof; 2: indication; 3: hint. For the purpose of this abstract always the
highest benefit level and evidence category claimed/assessed was taken into
account. RESULTS: Twenty-four EBAs were started in 2011: Tafamidis Meglumin,
Telaprevir, Abirateronacetat, Linagliptin, Pirfenidon, Boceprevir, Bromfenac, Ipili-
mumab, Fampridin, Belimumab, Belatacept, Dexmedetomidin, Cannabis Sativa,
Apixaban, Pitavastatin, Retigabin, Aliskiren/Amlodipin, Collagenase, Eribulin,
Cabazitaxel, Fingolimod, Regadenoson, Ticacrelor, Olmesartan/Amlodipin/Hydro-
chlorthiazid. The companies’ benefit claims/IQWiG benefit assessments included
the benefit level: major in 11/0 EBAs; significant 4/4; marginal 0/3; not quantifiable
1/2; no benefit 1/8; less benefit 0/0. Two Orphan indications were excluded from
this analysis; for five drugs no full dossier submissions and/or IQWiG assessments
were conducted (Bromfenac; Dexmedetomidin; Pitavastatin; Regadenoson; Olm-
esartan/Amlodipin/Hydrochlorthiazid) which resulted in a ‘no benefit’ conclusion
by the GBA. Companies claimed a proof in thirteen EBAs. IQWiG acknowledged a
proof in three EBAs. CONCLUSIONS: Both, evidence and benefit levels show major
differences between companies’ claims and IQWiG assessments. Most frequently
companies claimed a major benefit (11 EBAs) while IQWiG most frequently applied
the ‘no benefit’ category (8 EBAs).
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OBJECTIVES: Screening technologies are on the forefront of innovation and have
an impact on the care of patients in terms of identifying disease and appropriate
treatment options at an early stage. As such, screening technologies are of key
interest to health technology assessment (HTA) agencies in the United States (US)
and abroad. The objective of this research study is to evaluate existing technology
assessment standards for screening technologies in order to establish a best prac-
tice that may be implemented by US technology assessment organizations to
broaden the criteria used in assessments for screening products. METHODS: Qual-
itative interviews involving 12 HTA experts from the US, Canada, and the UK were
conducted. The experts represented HTA organizations that were for profit, not for
profit, government agencies, private payers, and academic medical centers. While
quantitative analysis of the levels of evidence required by HTA organizations for
screening products would produce a desirable study design, the findings from the
literature review indicated that quantitative evidence does not exist.RESULTS:The
results of this study indicate that the best practices should include criteria to sup-
port screening reliability, sensitivity and specificity; evaluate data to identify ap-
propriate patient populations; reference to the natural course of the disease; con-
sider ethical implications; and the impact of cost. CONCLUSIONS: HTA criteria
specific to the evaluation of screening products would positively impact HTA stake-
holders such as HTA organizations, their clients, patients, as well as technology
innovators. Best practices designed to help HTA organizations choose criteria that
are focused on screening technologies will help to identify whether relevant pa-
tient populations for the technology exist. In so doing, levels of evidence and data
requirements would be more transparent to screening technology innovators and
patients. Cost should be a part of the assessment to understand the cost and benefit
of using the product in specific patient populations for appropriate clinical decision
making.
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OBJECTIVES: Estimating the critical threshold value from previous reimbursement
decisions is one of the several methods to determine a cost effectiveness threshold.
The methodology is based on analyzing the relationship between the Incremental
Cost Effectiveness Ratio (ICER) of the assessed health technologies, and the reim-
bursement decisions. Our study tries to examine if there is any relationship be-
tween cost effectiveness and decision making in Hungary by analyzing data ab-
stracted from HTA appraisals and health economic studies. METHODS: The
members of the HTA Department examined the submissions containing a cost-
utility analysis which were assessed by the Hungarian HTA Office since 2004. We
created a database in which we summed up the cost/QALY values of the examined
submissions and HTA reports. We analyzed the appraisal determinations of the
HTA Committee regarding the assessed submissions in order to examine the like-
lihood of a positive/negative decision according the level of the assessed pharma-
ceutical’s ICER value. We searched for the technology with the highest ICER value,
which got reimbursed. RESULTS: We examined 165 submissions which contained
a cost-utility analysis that have arrived to our Department. Our results suggest that
there is only a weak correlation (r0,14) between the level of the calculated ICER
and the reimbursement decisions. We found, that the highest ICER which resulted
a positive reimbursement decision was 9 500 000 HUF/QALY (32 000 EUR).
CONCLUSIONS: One of the several methods to determine a threshold value is to
examine the relationship between previous reimbursement decisions and ICER
values calculated in health economic appraisals. However one must take into ac-
count, that estimating a threshold value based on prior decisions has limitations,
as reimbursement decisions are almost never made based on ICER ratios alone.
This could be the main reason our study only showed a weak correlation between
the level of calculated ICERs and the outcomes of the determinations.
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OBJECTIVES: To identify, using HTAinSite, if and how manufacturers have used
improved patient compliance as a value argument for their product in submissions
to the National Institute for Health and Clinical Excellence (NICE). We analysed if
and how compliance data were presented, how they were received by NICE, and if
they were an influential factor in NICE’s decision making.METHODS: A key phrase
search in HTAinSite was used to identify instances of ‘compliance’ and ‘adherence’
in manufacturer submissions and NICE technology appraisal (TA) documents. Af-
ter review for relevance, information was extracted and used to conduct a qualita-
tive analysis. RESULTS: Fifteen manufacturer’s submissions and 12 TAs reported
an improvement in compliance as a value argument for their drug. Factors used to
justify improved compliance included improved convenience, a reduction in ad-
verse events, increased treatment choice, and improved route of administration. In
8 of 13 TAs (relating to 11 manufacturer submissions), NICE state that the compli-
ance argument was considered by the Committee. In the remaining 5 TAs, despite
inclusion of a compliance argument by manufacturers in their submissions, the
Committee made no reference to it in the TA. Interestingly, only three manufac-
turers explicitly reported evidence supporting their compliance argument; how-
ever, the Committee discussed this in all of the associated TAs. The impact of
improved compliance on clinical outcomes or cost-effectiveness was frequently
not clearly reported by manufacturers or NICE. NICE did not explicitly cite compli-
ance as an influential factor in their final decision in any TAs. CONCLUSIONS: The
committee are more likely to consider a compliance argument if there is a clear
clinical rationale and it is accompanied by supporting data. Although compliance
arguments are considered by the Committee, NICE have not explicitly stated to
have used them to influence final decisions.
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THE EARLY BENEFIT ASSESSMENT OF DRUGS THAT ARE LAUNCHED BEFORE
2011
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